Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiSaver for acute myocardial infarction
ACTRN12626000412336Phase 2Not yet recruiting
- Sponsor
- HONYA Medical
- Start
- Apr 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of MiSaver in myocardial infarction (MI) (3 arms), sponsored by HONYA Medical. Primary endpoints: Change in left ventricular ejection fraction and Change in NYHA functional classification. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
MiSaver
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ACTRN12626000412336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000412336.